BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2022 9:38:18 AM | Browse: 453 | Download: 983
 |
Received |
|
2022-03-09 10:59 |
|
Peer-Review Started |
|
2022-03-09 11:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-17 10:20 |
|
Revised |
|
2022-05-10 09:20 |
|
Second Decision |
|
2022-06-27 03:08 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-06-27 18:58 |
|
Articles in Press |
|
2022-06-27 18:58 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-06-22 02:29 |
|
Typeset the Manuscript |
|
2022-07-01 08:12 |
|
Publish the Manuscript Online |
|
2022-07-22 09:38 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Review |
| Article Title |
Nanomedicine approaches for treatment of hematologic and oncologic malignancies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Polyxeni Nteli, Danae Efremia Bajwa, Dimitrios Politakis, Charalampos Michalopoulos, Anastasia Kefala-Narin, Efstathios P Efstathopoulos and Maria Gazouli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Maria Gazouli, PhD, Professor, Department of Basic Medical Sciences, Medical School, National and Kapodistrian University of Athens, Michalakopoulou 176, Athens 11527, Greece. mgazouli@med.uoa.gr |
| Key Words |
Nanomedicine; Cancer; Immunotherapy; Gene; Cell therapy |
| Core Tip |
Despite many years of fundamental and clinical examination and preliminaries of promising new treatments, cancer stays a significant reason for dreariness and mortality. Ongoing investigations propose that nanomedicine gives benefits over conventional treatments for cancer therapy. Immunotherapeutic strategies, such as cancer vaccines, immunomodulatory agents, immune checkpoint inhibitors, natural killer cells, peptides, nucleic acids, and chimeric antigen receptor T-cells, have augmented the development of this treatment either by stimulating cells or blocking the so-called immune checkpoint pathways. The efficacy of nanomedicine treatments and the examination of the advancement in the synergistic plan of immune-targeting combination therapies reviewed in this manuscript have been validated in clinical trials. The field of nanomedicine, therefore, generates new approaches regarding oncologic malignancies. |
| Publish Date |
2022-07-22 09:38 |
| Citation |
Nteli P, Bajwa DE, Politakis D, Michalopoulos C, Kefala-Narin A, Efstathopoulos EP, Gazouli M. Nanomedicine approaches for treatment of hematologic and oncologic malignancies. World J Clin Oncol 2022; 13(7): 553-566 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i7/553.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i7.553 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
